In the United Kingdom, the government is hoping weight loss drugs might improve public finances, eyeing their use to help ...

As revenues fall in diabetes treatments, has the industry found a new revenue driver in weight-loss treatments ... the FDA for type 2 diabetes in May 2022, and, ahead of any additional approval ...

The new weight-loss drugs have created “a hope and optimism ... by at least 5 percent in most participants after 56 weeks. A 2022 trial of 201 teens aged 12 to 18 reported a higher treatment ...

with these new uses, around a fifth of Medicare’s population, some 16m patients, could have access by 2026. At the same time, competition is likely to make weight-loss drugs both better and cheaper.

But now, a new study in The New England Journal of Medicine shows that they may want to consider a self-injection option – of the weight loss drug semaglutide. People with moderate ...

As the popularity of GLP-1 meds like Wegovy and Zepbound grows, fewer Americans are turning to weight-loss surgeries to trim their waistlines, a new report finds.

Oct 30 (Reuters) - The lowest dose of Novo Nordisk's (NOVOb.CO), opens new tab weight-loss drug ... on the U.S. Food and Drug Administration's shortage list since early 2022.

GLP-1 drugs like Wegovy (NVO) might help with weight loss, but they aren’t leading to lower health care costs yet, according to a new analysis of U.S. health insurance claims. A review by ...

The NHS's latest Health Survey for England shows in 2022, 29% of adults in England ... Streeting said he was expecting "demand" for new weight-loss drugs to outstrip NHS supplies.